ONCAlert | Upfront Therapy for mRCC

Searched Activities for "chronic myeloid leukemia"

This search found 211 results in 14 ms.
Nov 12, 2019 — The emergence of resistance mutations in patients with cancer who receive targeted therapies is an expected development that will require new diagnostic methods of identifying the mechanisms through which these alterations occur, according to Fei Dong, MD, during the 2019 Association for Molecular Pathology Annual Meeting.
 
Nov 12, 2019 — In an interview with Targeted Oncology, Eytan M. Stein, MD, reviews the current treatment landscape of acute myeloid leukemia, underscores the importance of molecular monitoring, and highlights where the field is headed.
Nov 08, 2019 — A technique involving BH3 profiling is emerging as a promising drug discovery tool for assessing whether a tumor is primed for cell death and would respond to anticancer therapy, according to a presentation at the 2019 Association for Molecular Pathology Annual Meeting.
Nov 05, 2019 — Pegfilgrastim-bmez, a biosimilar of pegfilgrastim, is now FDA approved to decrease the incidence of infection caused by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive therapy, according to a press release from Sandoz Inc., a division of Novartis. LA-EP2006 is already being sold in Europe and the developer now plans to bring the drug to the United States this year. 
 
Nov 05, 2019 — During a Targeted Oncology live case-based peer perspectives discussion, Ruben A. Mesa, MD, discussed risk assessment and treatment options available based on these assessments for patients with primary myelofibrosis with a group of physicians. Mesa, director of the UT Health San Antonio Cancer Center, explained these treatment options based on a case scenario of a patient with PMF.
Oct 31, 2019 — During a recent Targeted Oncology live case-based peer perspectives event, Olga Frankfurt, MD, discussed the complications that could development during the treatment of patients with graft-vs-host disease. Frankfurt explained these complications in the context of a patient who develops acute GVHD after undergoing hematopoietic cell transplant.
Oct 21, 2019 — During a Targeted Oncology tweet chat, Naveen Pemmaraju, MD, and Aaron Gerds, MD, MS, led a discussion on a patient case with myelofibrosis. They reviewed the options from a Twitter poll and how they would approach treatment of this particular patient.
Sep 20, 2019 — In an interview with Targeted Oncology, Prithviraj Bose, MD, reviewed his thoughts on identifying and treating progression in myelofibrosis, which he recently presented on during the 2019 SOHO Annual Meeting.
Sep 20, 2019 — Qandamp A With Moshe Yair Levy, MD: Weighing Risks and Benefits With the Use of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Sep 20, 2019 — Chronic myeloid leukemia is a rare type of cancer, and tyrosine kinase inhibitors have become the standard guideline-recommended treatment for patients with BCR-ABL1-positive or Ph-positive CML.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.